搜索到 1000 条关于 네이버 해외축구 et18.top 더킹카지노 조작 소울 카지노 Games global 에볼루션 바카라 총판 ozq 的文章

高手必备:18 种常用静脉泵入药物用法

2021.03.05 高手必备:18 种常用静脉泵入药物用法

常用的静脉泵入药物怎么配比你还记得么?今天盘点一下 18 种常用静脉泵入药物用法,再也不用埋头苦算了。1. 硝酸甘油 5 mg/mL50 mg + NS 40... ug/Kg/min,18 mg + NS 41 mL/iv 泵入,5 mL/h,常用剂量为 0.1~2.0 ug/kg/min,报告最大剂量可达 10.0
高手必备:18 种常用静脉泵入药物用法

2019.11.27 高手必备:18 种常用静脉泵入药物用法

常用的静脉泵入药物怎么配比你还记得吗?今天盘点一下 18 种常用静脉泵入药物用法,再也不用埋头苦算了。1. 硝酸甘油 5 mg/mL50 mg + NS 40...为:0.5 ug/Kg/min,18 mg + NS 41 mL/iv 泵入,5 mL/h,常用剂量为 0.1~2.0 ug/kg/min,报告最大剂量可达 10.0
礼来投资 18 亿美元联合 CureVac 进军 mRNA 癌症疫苗领域

2017.10.21 礼来投资 18 亿美元联合 CureVac 进军 mRNA 癌症疫苗领域

据 Firecebiotech 于 2017 年 10 月 18 日报道,礼来公司正在与 CureVac 合作开发五种 mRNA 癌症疫苗,并为此投资 18 亿美元。这项交易标志着礼来将着眼于一个新兴领域,即利用 mRNA 来诱导免疫系统对抗肿瘤。礼来公司正在支付 5000 万美元的预付款和 4500 万欧元的股权
2014全球畅销药TOP10 总销售额达830亿

2015.03.17 2014全球畅销药TOP10 总销售额达830亿

为自己的明星药物寻找“继承者”。从赛诺菲胰岛素新药Toujeo的上市策略来看,其欲成为当前畅销药物排行榜TOP 10中第3只胰岛素产品的雄心昭然若揭。此外,罗氏

2018.07.06 清华品驰 DBS-研究进展

, et al: Neuromodulation 2012. 140脑起搏器与神经调控技术. 李路明: 生命科学仪器 2015.神经调控装置国产化研究进展...: from stimulation to recording. Qian X, Chen Y, Ma B, et al:Science Bulletin
卫生部流感诊断与治疗专家组发布流感诊断与治疗指南中国版(2011)

2011.11.03 卫生部流感诊断与治疗专家组发布流感诊断与治疗指南中国版(2011)

% except for human avian flu). The past 300 years has witnessed at least six global... will continue to be a medical matter of top priority.To further promote
2013年ESH/ESC动脉高血压管理指南

2013.08.13 2013年ESH/ESC动脉高血压管理指南

global risk for mortality in the world”1. It continues to affect... since the last revision (in 2007), with 18 specific diagnostic and therapeutic
Emerging and Re-emerging Infectious Diseases

2011.12.28 Emerging and Re-emerging Infectious Diseases

Behaviour-16Antimicrobial Drug Resistance-17CONTD-18... out by whom-46What skills are needed-47Global Disease
Emerging and Re-emerging Infectious Diseases

2011.12.28 Emerging and Re-emerging Infectious Diseases

Behaviour-16Antimicrobial Drug Resistance-17CONTD-18... out by whom-46What skills are needed-47Global Disease
人乳具抗HCV活性

2013.11.13 人乳具抗HCV活性

Background. Hepatitis C virus (HCV) is spread through direct contact with blood, although alternative routes of transmission may contribute to the global burden. Perinatal infection occurs in up to 5% of HCV-infected mothers, and presence of HCV RNA in breast milk has been reported. We investigated the influence of breast milk on HCV infectiousness.Methods/Results. Human breast milk reduced HCV infectivity in a dose-dependent manner. This effect was species-specific because milk from various animals did not inhibit HCV infection. Treatment of HCV with human breast milk did not compromise integrity of viral RNA or capsids but destroyed the lipid envelope. Fractionation of breast milk revealed that the antiviral activity is present in the cream fraction containing the fat. Proteolytic digestion of milk proteins had no influence on its antiviral activity, whereas prolonged storage at 4°C increased antiviral activity. Notably, pretreatment with a lipase inhibitor ablated the antiviral activity and specific free fatty acids of breast milk were antiviral.Conclusions. The antiviral activity of breast milk is linked to endogenous lipase-dependent generation of free fatty acids, which destroy the viral lipid envelope. Therefore, nursing by HCV-positive mothers is unlikely to play a major role in vertical transmission.
JID :白藜芦醇可增强替诺福韦的抗HIV-1活性

2013.09.21 JID :白藜芦醇可增强替诺福韦的抗HIV-1活性

Background. Targeting host-cell pathways to increase the potency of nucleoside/nucleotide analog reverse transcriptase inhibitors (NRTIs) is an important strategy for clinical investigation. Resveratrol is a natural product that inhibits cellular ribonucleotide reductase, prolonging the S phase of the cell cycle and preferentially lowering dATP levels.Methods. We performed in vitro evaluation of resveratrol on the antiviral activity of adenosine analog tenofovir (TFV) against sensitive and drug-resistant human immunodeficiency virus type 1 (HIV-1), from subtypes B and C, in primary cells.Results. Resveratrol enhanced the antiviral activity of TFV by up to 10-fold and restored susceptibility of TFV-resistant viruses. Resveratrol prevented wild-type HIV-1 from developing phenotypic resistance to TFV. Notably, resveratrol enhanced TFV activity against sensitive and resistant HIV-1 from both subtypes B and C.Conclusions. Prolonged wide-scale use of thymidine analogs in the setting of viral failure has limited the efficacy of second-line NRTI-based regimens in Africa. Moreover, the extensive use of ddI and d4T has led to high frequencies of the K65R mutation, further compromising TFV efficacy. In light of increasing resistance to commonly used NRTIs in global HIV treatment programs, targeting nucleoside biosynthesis with resveratrol, or derivatives with improved bioavailabilities, is a potential strategy to maintain, enhance, and restore susceptibility of commonly used NRTIs.

2012.09.19 第1届免疫疾病世界研讨会

Organized by the professional organization- China Liaoning Society for Immunology and Institute of Immunology, China Medicinal University, the 1st Annual International Symposium on Immune Diseases is designed to provide a small and cross disciplinary carefully selected current topics in immunology, from the basic science to clinical treatment. Over 300 global specialists are anticipated to get together to present and share their cutting-edge developments and up-to-date researches in pathogenesis, diagnosis, prevention, treatment, and clinical presentation of important immune diseases. We are convinced ISID-2010 will definitely offer an idea platform for promotion and collaboration for relevant companies and institutes of their technologies, products and services.The 1st Annual International Symposium on Immune Disease 2010 (ISID-2010) will include either oral or poster presentations in both academic and industrial settings. All the faculty, academic, clinical and industrial researchers will have their own presentation means to join this event.The conference venue, Beijing is the bilingual and multicultural capital city of China. On August 8, 2008, Beijing brought the world a great surprise for the Olympics opening ceremony. We are sure Beijing will provide an ideal location for what promises to be an exciting and memorable meeting.We look forward to seeing you in Beijing for a stimulating and enjoyable Conference!会议主席:中国医科大学院士 陈洪铎教授会议副主席:中国医科大学 吕昌龙教授会议执行主席:中国医科大学 单凤平教授
2025 年全球肥胖患病率男性将 18% 女性将超 21%

2016.04.12 2025 年全球肥胖患病率男性将 18% 女性将超 21%

至 2014 年各区域的男性和女性平均 BMI 以及 BMI 各分类下:(1)体重偏轻:BMI<18·5 kg/m2 ;(2)18.5 kg/m2&nbsp...发展,截至 2025 年,全球男性肥胖患病率会到达 18%,女性会超过 21%,男性严重肥胖的患病率会超过 6%,女性会超过 9%,体重偏轻的高发病率仍会是世界

2009.07.19 7月18日第五场讲座(主持人:李正仪 林航 陈春富)

卒中的院前干预17:35-17:50  POC测定在卒中预防中的价值(管阳太) 17:50-18:10  卫星会议 18:10    “
礼来拓展免疫肿瘤领域 与 CureVac 签订 18 亿美元协议

2017.10.23 礼来拓展免疫肿瘤领域 与 CureVac 签订 18 亿美元协议

PMLiVE 于 10 月 19 日报道,礼来显著加大对免疫肿瘤的关注,该公司与德国生物制药集团 CureVac 签署了一项价值逾 18 亿美元的协议。这对合作伙伴将开发多达 5 款癌症疫苗产品,并在合作过程中有可能开发新的药物。该协议的核心是信使 RNA(mRNA) 技术,这是该技术在免疫肿瘤学领域的首次广泛探索
新冠疫情爆发后,已累计有 54 篇相关研究发表(附论文下载入口)

2020.02.01 新冠疫情爆发后,已累计有 54 篇相关研究发表(附论文下载入口)

: https://doi.org/10.1101/2020.01.23.916726 18、通过结合同源建模、分子对接和结合自由能计算的整合方法,预测奈非那韦... in Wuhan City ChinaImaiN, Dorigattig I, Cori A, et al. Estimating the potential
管忠震教授谈 CSCO 18 年的发展历程

2015.09.22 管忠震教授谈 CSCO 18 年的发展历程

18 届全国临床肿瘤学大会(CSCO2015)上,丁香园有幸邀请到管忠震教授和我们分享了 CSCO 成立之初的事。随着会员数越来越多,CSCO 组织了一个继续教育为主的平台,推动了临床研究的发展。ccvideo
一表鉴别!哮喘、慢阻肺诊治 10 要点

2018.03.27 一表鉴别!哮喘、慢阻肺诊治 10 要点

: 857-873.2.Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2017.3.Global Strategy for Diagnosis, Management and Prevention of COPD
上一页 1 2 3 ... 18 19 20 ... 48 49 50 下一页 到第